What does cell therapy in cancer look like today, and what will this exploding field look like in the future? This has been a milestone year for cell therapy, with FDA approval of the first adoptive CAR T-cell therapies for acute myeloid leukemia and some large B-cell lymphomas. But there is much more on the horizon. Watch Jeff Bluestone, PhD, president and CEO of the Parker Institute for Cancer Immunotherapy, and Crystal Mackall, MD, center director of the Parker Institute at Stanford Medicine, discuss new approaches, strategies and technologies for cell-based therapies that will continue to transform precision medicine. This talk was recorded at the Precision Medicine World Conference in January 2018 in Silicon Valley.
You Might Also Like...
Clinical Trials, Research Updates
CD22 CAR-T Therapy Shows Results in Leukemia, Study Shows, But Could a Dual CAR-T Deliver the One-Two Punch to Avoid Relapse?
November 20, 2017
Using Yourself to Fight Cancer with Jeff Bluestone, President and CEO of the Parker Institute for Cancer Immunotherapy
July 12, 2017